The effect of antihypertensive treatment on the incidence of stroke and cognitive decline in the elderly: a meta-analysis

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 WHO. The top ten causes of death (2012). www.who.int/mediacentre/factsheets/fs310/en/Google Scholar
• 2 WHO. World Health Report 2013: Research for Universal Health Coverage. WHO Press, Geneva, Switzerland (2013).Google Scholar
• 3 Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 370(9587), 591–603 (2007).Crossref, Medline, CAS, Google Scholar
• 4 Rapsomaniki E, Timmis A, George J et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 383(9932), 1899–1911 (2014).Crossref, Medline, Google Scholar
• 5 Lipsitz LA. A 91-year-old woman with difficult-to-control hypertension: a clinical review. JAMA 310(12), 1274–1280 (2013).Crossref, Medline, CAS, Google Scholar
• 6 Cherubini A, Lowenthal DT, Paran E, Mecocci P, Williams LS, Senin U. Hypertension and cognitive function in the elderly. Dis. Mon. 56(3), 106–147 (2010).Crossref, Medline, Google Scholar
• 7 Di Bari M, Pahor M, Franse LV et al. Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trial. Am. J. Epidemiol. 153(1), 72–78 (2001).Crossref, Medline, CAS, Google Scholar
• 8 Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 265(24), 3255–3264 (1991).Crossref, Medline, Google Scholar
• 9 Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338(8778), 1281–1285 (1991).Crossref, Medline, CAS, Google Scholar
• 10 Forette F, Seux ML, Staessen JA et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352(9137), 1347–1351 (1998).Crossref, Medline, CAS, Google Scholar
• 11 Staessen JA, Thijs L, Birkenhager WH, Bulpitt CJ, Fagard R. Update on the systolic hypertension in Europe (Syst-Eur) trial. The Syst-Eur Investigators. Hypertension 33(6), 1476–1477 (1999).Crossref, Medline, CAS, Google Scholar
• 12 Gong L, Zhang W, Zhu Y et al. Shanghai Trial Of Nifedipine in the Elderly (STONE). J. Hypertens. 14(10), 1237–1245 (1996).Crossref, Medline, CAS, Google Scholar
• 13 Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens. 21(5), 875–886 (2003).Crossref, Medline, CAS, Google Scholar
• 14 Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J. Hypertens. 16(12 Pt 1), 1823–1829 (1998).Crossref, Medline, CAS, Google Scholar
• 15 Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 304(6824), 405–412 (1992).Crossref, Medline, Google Scholar
• 16 Carr MJ, Bao Y, Pan J, Cruickshank K, Mcnamee R. The predictive ability of blood pressure in elderly trial patients. J. Hypertens. 30(9), 1725–1733 (2012).Crossref, Medline, CAS, Google Scholar
• 17 Peters R, Beckett N, Forette F et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 7(8), 683–689 (2008). •• Only trial with cognitive outcomes meeting inclusion criteria in the very elderly.Crossref, Medline, CAS, Google Scholar
• 18 Zhang Y, Zhang X, Liu L, Zanchetti A, Group FS. Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur. Heart J. 32(12), 1500–1508 (2011).Crossref, Medline, Google Scholar
• 19 Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 358(18), 1887–1898 (2008). •• Only trial with stroke outcomes meeting inclusion criteria in the very elderly.Crossref, Medline, CAS, Google Scholar
• 20 Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350(9080), 757–764 (1997).Crossref, Medline, CAS, Google Scholar
• 21 Lever AF, Brennan PJ. MRC trial of treatment in elderly hypertensives. Clin. Exp. Hypertens. 15(6), 941–952 (1993).Crossref, Medline, CAS, Google Scholar
• 22 Leenen FH, Nwachuku CE, Black HR et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 48(3), 374–384 (2006).Crossref, Medline, CAS, Google Scholar
• 23 ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288(23), 2981–2997 (2002).Crossref, Medline, Google Scholar
• 24 Hansson L, Lindholm LH, Ekbom T et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354(9192), 1751–1756 (1999).Crossref, Medline, CAS, Google Scholar
• 25 Wing LM, Reid CM, Ryan P et al. A comparison of outcomes with angiotensin-converting – enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med. 348(7), 583–592 (2003).Crossref, Medline, CAS, Google Scholar
• 26 Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359(9311), 995–1003 (2002).Crossref, Medline, CAS, Google Scholar
• 27 Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363(9426), 2022–2031 (2004).Crossref, Medline, CAS, Google Scholar
• 28 Julius S, Weber MA, Kjeldsen SE et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 48(3), 385–391 (2006).Crossref, Medline, CAS, Google Scholar
• 29 Ogihara T, Matsuzaki M, Umemoto S et al. Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial. Hypertens. Res. 35(4), 441–448 (2012).Crossref, Medline, CAS, Google Scholar
• 30 Schrader J, Luders S, Kulschewski A et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36(6), 1218–1226 (2005).Crossref, Medline, CAS, Google Scholar
• 31 Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 42(3), 239–246 (2003).Crossref, Medline, Google Scholar
• 32 Collier DJ, Poulter NR, Dahlof B et al. Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). J. Hypertens. 29(3), 583–591 (2011).Crossref, Medline, CAS, Google Scholar
• 33 Malacco E, Mancia G, Rappelli A et al. Treatment of isolated systolic hypertension: the SHELL study results. Blood Press. 12(3), 160–167 (2003).Crossref, Medline, CAS, Google Scholar
• 34 Group JS. Principal results of the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS). Hypertens. Res. 31(12), 2115–2127 (2008).Crossref, Medline, Google Scholar
• 35 Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356(9227), 366–372 (2000).Crossref, Medline, CAS, Google Scholar
• 36 Staessen JA, Thijisq L, Fagard R et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe trial. J. Hypertens. 22(4), 847–857 (2004).Crossref, Medline, CAS, Google Scholar
• 37 Mulrow C, Lau J, Cornell J, Brand M. Pharmacotherapy for hypertension in the elderly. Cochrane Database Syst. Rev. 2, CD000028 (2000). • Cochrane review on the effect of antihypertensive therapy on morbidity and mortality in the elderly.Google Scholar
• 38 Neal B, Macmahon S, Chapman N, Blood Pressure Lowering Treatment Trialists Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet 356(9246), 1955–1964 (2000).Crossref, Medline, CAS, Google Scholar
• 39 Forette F, Seux ML, Staessen JA et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch. Int. Med. 162(18), 2046–2052 (2002). • Extended trial follow-up for cognitive outcomes.Crossref, Medline, Google Scholar
• 40 Mcguinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst. Rev. 4, CD004034 (2009). • Cochrane review on antihypertensive therapy effect on cognitive outcomes in patients without existing cerebrovascular disease.Google Scholar
• 41 Feigin V, Ratnasabapathy Y, Anderson C. Does blood pressure lowering treatment prevents dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease? J. Neurol. Sci. 229–230, 151–155 (2005).Crossref, Medline, Google Scholar